CL2018002960A1 - Tratamiento de dermatitis atópica canina. - Google Patents

Tratamiento de dermatitis atópica canina.

Info

Publication number
CL2018002960A1
CL2018002960A1 CL2018002960A CL2018002960A CL2018002960A1 CL 2018002960 A1 CL2018002960 A1 CL 2018002960A1 CL 2018002960 A CL2018002960 A CL 2018002960A CL 2018002960 A CL2018002960 A CL 2018002960A CL 2018002960 A1 CL2018002960 A1 CL 2018002960A1
Authority
CL
Chile
Prior art keywords
treatment
atopic dermatitis
compositions
cad
prevention
Prior art date
Application number
CL2018002960A
Other languages
English (en)
Inventor
Kaspars Tars
Original Assignee
Benchmark Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benchmark Animal Health Ltd filed Critical Benchmark Animal Health Ltd
Publication of CL2018002960A1 publication Critical patent/CL2018002960A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES, COMPOSICIONES INMUNOGÉNICAS O DE VACUNA Y COMPOSICIONES FARMACÉUTICAS PARA LA PREVENCIÓN O TRATAMIENTO DE DERMATITIS ATÓPICA CANINA (CAD). ADEMÁS, LA INVENCIÓN PROPORCIONA MÉTODOS PARA LA PREVENCIÓN O TRATAMIENTO DE CAD. LAS COMPOSICIONES DE LA INVENCIÓN INDUCEN RESPUESTAS INMUNES EFICIENTES, EN PARTICULAR RESPUESTAS DE ANTICUERPOS, EN PERROS Y, POR LO TANTO, SON ÚTILES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE CAD.
CL2018002960A 2016-04-27 2018-10-17 Tratamiento de dermatitis atópica canina. CL2018002960A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16167264 2016-04-27

Publications (1)

Publication Number Publication Date
CL2018002960A1 true CL2018002960A1 (es) 2019-01-25

Family

ID=56024099

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002960A CL2018002960A1 (es) 2016-04-27 2018-10-17 Tratamiento de dermatitis atópica canina.

Country Status (17)

Country Link
US (1) US10946078B2 (es)
EP (1) EP3448422A1 (es)
JP (2) JP7039561B2 (es)
KR (2) KR20220162800A (es)
CN (2) CN109562156B (es)
AR (1) AR108333A1 (es)
AU (2) AU2017256727B2 (es)
BR (1) BR112018071965A2 (es)
CA (1) CA3019653A1 (es)
CL (1) CL2018002960A1 (es)
CO (1) CO2018011087A2 (es)
EA (1) EA201892003A1 (es)
MX (1) MX2022009171A (es)
NZ (1) NZ747512A (es)
UA (1) UA126852C2 (es)
WO (1) WO2017186813A1 (es)
ZA (1) ZA201806503B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009296A (ko) * 2017-12-11 2021-01-26 유비아이 아이피 홀딩스 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물
US11433139B2 (en) 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
BR112020017703A2 (pt) 2018-03-16 2021-03-09 Zoetis Services Llc Anticorpos monoclonais de interleucina-31 para uso veterinário
MX2021007285A (es) * 2018-12-20 2021-09-23 Saiba AG Particulas similares a virus del cmv modificadas por fusion.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
WO2003024481A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
NZ554387A (en) 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2008112674A1 (en) 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP2016509671A (ja) 2013-01-04 2016-03-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ オピオイド受容体のポジティブアロステリックモジュレーターおよびサイレントアロステリックモジュレーター
WO2015042596A1 (en) 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié

Also Published As

Publication number Publication date
CN116688110A (zh) 2023-09-05
EP3448422A1 (en) 2019-03-06
MX2022009171A (es) 2022-08-17
AU2022291431A1 (en) 2023-03-30
JP2019515957A (ja) 2019-06-13
ZA201806503B (en) 2019-07-31
AR108333A1 (es) 2018-08-08
CN109562156B (zh) 2023-03-10
JP7273214B2 (ja) 2023-05-12
JP7039561B2 (ja) 2022-03-22
KR102469478B1 (ko) 2022-11-23
KR20220162800A (ko) 2022-12-08
US20190209668A1 (en) 2019-07-11
AU2017256727B2 (en) 2022-09-29
CA3019653A1 (en) 2017-11-02
BR112018071965A2 (pt) 2019-03-06
US10946078B2 (en) 2021-03-16
AU2017256727A1 (en) 2018-11-15
KR20190003948A (ko) 2019-01-10
EA201892003A1 (ru) 2019-05-31
NZ747512A (en) 2023-05-26
CN109562156A (zh) 2019-04-02
UA126852C2 (uk) 2023-02-15
WO2017186813A1 (en) 2017-11-02
JP2022078254A (ja) 2022-05-24
CO2018011087A2 (es) 2019-02-08

Similar Documents

Publication Publication Date Title
CL2018002960A1 (es) Tratamiento de dermatitis atópica canina.
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
BR112017024940A2 (pt) composições de óleo essencial e seu método
BR112018001187A2 (pt) materiais e métodos para melhorar as respostas imunes e funções de barreira de pele e/ou mucosa
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
ECSP16075416A (es) Anticuerpos de il-21
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
PH12017500003A1 (en) Vaccine composition for classical swine fever from plant and manufacturing method thereof
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
ECSP18070641A (es) Anticuerpos para il-17c
BR112017008097A2 (pt) método para tratar condições oculares
MX2017000869A (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
CL2016001906A1 (es) Vacunas contra el reovirus aviar.
BR112017025316A2 (pt) estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
BR112017011076A2 (pt) métodos e composições para prevenir ou reduzir infecções de plantas cultivadas por agentes patogênicos fúngicos e bacterianos
BR112016016672A2 (pt) Uso de uma composição
ITUB20152119A1 (it) Dispositivo per la sterilizzazione di oggetti e metodo di sterilizzazione associato.